A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma

Inclusion Criteria:

1. The patient's guardian signs an informed consent form and is willing to receivefollow-up according to the schedule of the trial;
2. Children of more than 3 months and under 5 years of age who have not received anyanti-cancer treatment;
3. The target eye must meet the following requirements: Clinically diagnosed as monocular retinoblastoma; According to the IIRC diagnosticcriteria, the treatment eye is classified as Group E stage without clinical high-riskfactors (Table 1); No refractive medium turbidity and/or pupillary abnormalities thataffect the fundus examination; IOP≤21mmHg.
4. Sufficient organ function at baseline.

Exclusion Criteria: Subjects with any of the following eye conditions:

1. Patients diagnosed as stage E retinoblastoma in one eye, but with high-risk factors:neovascular glaucoma; refractive interstitial opacity caused by anterior chamber,vitreous or subretinal hemorrhage; tumor invasion of optic nerve posterior to thecribriform plate and choroid (range of diameter> 2 mm), sclera, and anterior chamber;
2. Treatment-naïve pediatric patients; Patients with any of the following systemic diseases:
3. With a history of allergies or have allergic reactions to fluorescein sodium, with ahistory of allergies to protein products for treatment or diagnosis, and have allergicreactions to two or more drugs and/or non-drug factors, or suffering from allergicdiseases;
4. Low birth weight children, and severely growth-stunted children;
5. Children who need systemic treatment for other system diseases;
6. Any condition that should be excluded from the study in the opinion of theinvestigator.